Abstract：
OBJECTIVE: The tryptophanyl-tRNA synthetase 1 gene (WARS1), encodes a tryptophan-tRNA synthetase involved in the amino acidification of tryptophan-tRNA and has been reported to be involved in cancer cell growth, metastasis promotion, and drug resistance in a variety of cancers. This study investigated the clinical significance of WARS1 expression as a biomarker in gastric cancer tissues obtained from patients with locally advanced gastric cancer (GC) who underwent radical resection.
METHODS: WARS1 expression in GC tissues and adjacent normal gastric mucosa of 253 patients with pStage II/III GC who underwent curative resection was determined using quantitative polymerase chain reaction (PCR). Association of WARS1 expression levels, categorized into high and low expression based on the median expression levels, with clinicopathological factors and overall survival (OS) of these patients was assessed.
RESULTS: The low-WARS1 expression group had significantly higher serosal invasion, lymph node metastasis, lymphatic invasion, venous invasion, and pathological stage than did the high-WARS1 expression group. OS was significantly worse in the low- than in the high-WARS1 expression group (5-year survival 52.2% vs. 75.9%; p=0.0001). Furthermore, in multivariate analysis, low WARS1 expression was an independent predictor for poor OS (hazard ratio=2.101; 95% confidence interval=1.328-3.322; p=0.002).
CONCLUSIONS: In patients with locally advanced GC, after curative resection, WARS1 expression in GC tissue may be a useful prognostic marker.
METHODS: WARS1 expression in GC tissues and adjacent normal gastric mucosa of 253 patients with pStage II/III GC who underwent curative resection was determined using quantitative polymerase chain reaction (PCR). Association of WARS1 expression levels, categorized into high and low expression based on the median expression levels, with clinicopathological factors and overall survival (OS) of these patients was assessed.
RESULTS: The low-WARS1 expression group had significantly higher serosal invasion, lymph node metastasis, lymphatic invasion, venous invasion, and pathological stage than did the high-WARS1 expression group. OS was significantly worse in the low- than in the high-WARS1 expression group (5-year survival 52.2% vs. 75.9%; p=0.0001). Furthermore, in multivariate analysis, low WARS1 expression was an independent predictor for poor OS (hazard ratio=2.101; 95% confidence interval=1.328-3.322; p=0.002).
CONCLUSIONS: In patients with locally advanced GC, after curative resection, WARS1 expression in GC tissue may be a useful prognostic marker.
摘要：
目的：色氨酸-tRNA合成酶1基因（WARS1），编码一种色氨酸-tRNA合成酶，参与色氨酸-tRNA的氨基酸化，据报道参与癌细胞生长，转移促进，以及多种癌症的耐药性。这项研究调查了WARS1表达作为生物标志物在接受根治性切除术的局部晚期胃癌（GC）患者胃癌组织中的临床意义。
方法：采用定量聚合酶链反应（PCR）检测253例接受根治性切除的pStageII/III期GC患者GC组织和邻近正常胃粘膜中WARS1的表达。WARS1表达水平的关联，根据中位数表达水平分为高表达和低表达，评估了这些患者的临床病理因素和总生存期(OS).
结果：低WARS1表达组浆膜浸润明显增高，淋巴结转移,淋巴侵入，静脉侵入,病理分期高于WARS1高表达组。低表达组的OS显著低于高表达组(5年生存率52.2%vs.75.9%；p=0.0001）。此外，在多变量分析中，低WARS1表达是OS差的独立预测因子(风险比=2.101;95%置信区间=1.328-3.322;p=0.002).
结论：在局部晚期GC患者中，治愈性切除后，WARS1在GC组织中的表达可能是一个有用的预后标志物。
方法：采用定量聚合酶链反应（PCR）检测253例接受根治性切除的pStageII/III期GC患者GC组织和邻近正常胃粘膜中WARS1的表达。WARS1表达水平的关联，根据中位数表达水平分为高表达和低表达，评估了这些患者的临床病理因素和总生存期(OS).
结果：低WARS1表达组浆膜浸润明显增高，淋巴结转移,淋巴侵入，静脉侵入,病理分期高于WARS1高表达组。低表达组的OS显著低于高表达组(5年生存率52.2%vs.75.9%；p=0.0001）。此外，在多变量分析中，低WARS1表达是OS差的独立预测因子(风险比=2.101;95%置信区间=1.328-3.322;p=0.002).
结论：在局部晚期GC患者中，治愈性切除后，WARS1在GC组织中的表达可能是一个有用的预后标志物。
